Q3 FY2025 saw robust year-over-year revenue and profit growth, driven by strong performance in the chemicals segment and successful commercialization of new products. EBITDA margins remained strong, and the company maintained a debt-free balance sheet while investing in capacity expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.